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Biological dosimetry based on chromosome
aberration scoring in peripheral blood lymphocytes
enables timely assessment of the ionizing radiation
dose absorbed by an individual. Here, new Bayesian-
type count data inverse regression methods are
introduced for situations where responses are Poisson
or two-parameter compound Poisson distributed.
Our Poisson models are calculated in a closed form,
by means of Hermite and negative binomial (NB)
distributions. For compound Poisson responses,
complete and simplified models are provided. The
simplified models are also expressible in a closed
form and involve the use of compound Hermite
and compound NB distributions. Three examples
of applications are given that demonstrate the
usefulness of these methodologies in cytogenetic
radiation biodosimetry and in radiotherapy. We
provide R and SAS codes which reproduce these
examples.
1. Introduction
In spite of strict safety measures and regulations,
radiation accidents or unplanned exposures occur,
for instance in radiology services and radiotherapy
departments at hospitals, or using radiography cameras
in industry. There have also been some major radiation/
nuclear accidents, such as Chernobyl or Fukushima,
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Creative Commons Attribution License http://creativecommons.org/licenses/





that have affected many people [1]. In the event of a radiation accident, biological dosimetry
is essential for the timely determination of the radiation dose to which an individual has
been exposed. On the other hand, radiotherapy is commonly used to treat cancerous tumours,
and it is important to know the total absorbed blood dose to prevent possible complications
or side effects. Biological dosimetry relies on quantifying the amount of damage induced
by radiation at a cellular level, for instance by counting dicentrics or micronuclei. These
aberrations appear because when cells are exposed to radiation, breaks are induced in the
chromosomal DNA and the broken fragments may rejoin incorrectly. Therefore, the frequency
of chromosome aberrations increases with the amount of radiation and is a reliable and very
well-established biological indicator of radiation absorbed dose. Such information supports the
clinical management of a patient, enables rapid triage in the case of a large-scale radiation
incident and reassures the ‘worried well’ that they have not received a severe radiation dose.
At high acute whole body doses above 2 Gy, haematopoietic failure (or myelodysplasia) is the
primary threat associated with acute radiation syndrome which can be supported by early
treatment with cytokines or, at very high doses, bone marrow transplants [2]. To estimate the
dose absorbed by an individual, dose–effect calibration curves are required which are produced
by irradiating peripheral blood lymphocytes to a range of doses. The protocol and methodology
for such calibration experiments is described in a recent manual of the International Atomic
Energy Agency [3].
The usual approach for constructing the calibration curve is to irradiate n blood samples
from various healthy donor with several doses xi, i= 1, . . . ,n. Then, for each irradiated sample,
ni cells are examined and the numbers of observed chromosomal aberrations yij, j= 1, . . . ,ni
is recorded. For the dicentric assay, it is usually assumed that the counts yij follow a Poisson
distribution [4] or a compound Poisson distribution [5] whose mean is a function of xi and
a set of parameters β, i.e. E(yij) = f(xi, β). From the point of view of IAEA [3], β are the
calibration coefficients and f(xi, β) is the mean of aberrations per cell (called yield or frequency
of aberrations per cell, in the cytogenetics field). The parameters of this regression model
are usually estimated by maximum likelihood [6], and the MLE and its estimated variance–
covariance matrix are calculated and recorded. Therefore, in the case of an irradiated patient,
a blood sample is taken and m lymphocytes are scored obtaining the counts y˜1, . . . , y˜m. The
classical approach to estimate the absorbed dose x and its confidence limits is to use the inverse
regression method of Merkle [7], also described as a standard procedure in [3]. An improved
classical inverse regression method applied to Electron Paramagnetic Resonance dosimetry is
found in [8].
Bayesian approaches allow simple incorporation of prior information concerning the
circumstances of the exposure. Groer & Pereira [9] were the first to investigate the use of Bayesian
models in chromosome dosimetry, for neutron exposure, and since then several researchers have
used Bayesian methods in radiation biodosimetry. For instance, Di Giorgio & Zaretzky [10] used
a Bayesian approach to present the uncertainty on a biological dose estimate for a radiation
overexposed patient in Latin America: a Poisson model with a Jeffrey’s prior was used and it
was further demonstrated that the Bayesian approach allows presentation of probabilities for
dose ranges, which leads to a much more intuitive interpretation of the biological dosimetry
results. A review of these methods can be found in [11]. There is also one recent program,
CytoBayesJ [12], which provides some basic software tools for Bayesian analysis of cytogenetic
radiation dosimetry data.
In this paper, we present a new Bayesian-type method to use cytogenetic data to estimate
the dose to which a patient has been exposed. This method uses dose–effect calibration curves
estimated by the classical (frequentist) approach suggested in the IAEA manual. Therefore, our
new method has the advantage that allows reanalysis of many of the published examples of
radiation exposures that were studied using the classical methods. In addition, the method is in
fact a general inverse regression model for count responses that could also be applied in contexts




For the three routines implemented in the R statistical software (v. 3.1.1) run in the examples
(§§3a,b and 4a) see the electronic supplementary material. A SAS (v. 9.3) routine for model (a) (see
table 3) in §3a is also provided. A new R package called ‘radir’, which implements the Poisson
response models presented here, is available under request to the corresponding author.
2. A Bayesian-type inverse regression model
The Poisson distribution is usually used to describe the distribution of dicentric chromosomes per
cell when the patient has been irradiated with small doses and with a low linear energy transfer
(low-LET radiation). However, after exposure to high-LET, acute radiation, the distribution of
dicentrics per cell often presents overdispersion and therefore compound Poisson distributions
are preferred. The commonly compound Poisson distributions in biodosimetry are the Neyman
A (NA) [13], the negative binomial (NB) [14] and recently the family of rth-order univariate
Hermite distributions [15]. These compound Poisson distributions, also known as stopped-
Poisson distributions, can be justified by a simple physical model of chromosomal aberration
formation: the particles traverse the cell nucleus following a Poisson process and, for each particle,
there is a probability (the generalizing distribution) to produce k aberrations. Then the number
of aberrations follows a compound Poisson distribution. In other words, a random variable Y





where N is a count data random variable and ξ1, ξ2, . . . are independent, identically distributed
random variables that are also independent of N. In the case where N is Poisson, Y is said to follow
a compound Poisson distribution. The distribution of ξi is called the generalizing distribution. In
particular when the distribution of ξi is Poisson, the distribution of Y is an NA, when ξi follows
a logarithmic distribution, Y is NB distributed, and when ξi is distributed as a binomial with a
number of trials equal to 2, then Y follows a Hermite distribution [16]. This can be expressed
according to the Gurland’s notation [16,17] as N
∨
ξ . In particular, parametrizing with respect to
the population mean μ and dispersion index δ (the ratio of the variance to the mean σ 2/μ) we
have the symbolic representation,
— NA(μ, δ) ∼ Pois(μ/(δ − 1))∨ Pois(δ − 1)
— NB(μ, δ) ∼ Pois(μ log(δ)/(δ − 1))∨ log((δ − 1)/δ)
— Herm(μ, δ) ∼ Pois(μ/2(δ − 1))∨ Bin(2, δ − 1).
Properties, formulae and algorithms to calculate the probabilities of these distributions can
be found in [16]. In brief, they are partially closed under addition [18], the maximum-
likelihood estimator of the population mean is the sample mean and they are also members
of the discrete exponential dispersion family of distributions. These properties are shared with
other distributions potentially useful in biodosimetry, such as Polya Aeppli or Poisson-inverse
Gaussian. See [18] for more properties and characterizations of these distributions. In particular,
given a random variable Y (with mean μ and dispersion index δ) belonging to one of these models,
the sum of n independent copies of Y also belongs to the same model having the same dispersion
index and a mean equal to nμ. Moreover, if δ is known, the sum of the observations is a sufficient
statistic for μ, containing all the information of the model. This is an important property that will
be used in §4.
Let D= {(xi, yij)}, i= 1, . . . ,n, j= 1, . . . ,ni be a calibration dataset where each yij represents a
count data observation which will be assumed to follow a Poisson distribution or a two-parameter
compound Poisson distribution. Here xi are the values of the independent variable, dose in the
case of cytogenetic radiation biodosimetry. The number of different exposed doses is n and ni is




function E(yij) = f(xi, β), β ∈Rp. Moreover, for compound Poisson modelling, we assume that the
dispersion index is a constant (δ). In practice, this assumption could be verified by plotting the
empirical values of the dispersion index (s2yi/y¯i.) against the xi. However, we could assume another
relationship between the independent variable and the dispersion index. Therefore, from now,
we will consider the dispersion coefficient δ not to depend on xi, and then the domain of the
parameters is Θ = {β, δ}. Note that for the Poisson model δ = 1 and the domain of the parameters
is just Θ = {β}.
Let p(yij = k) = p(k|μ, δ) be the probability mass function of the model, parametrized in terms
of its population mean and dispersion index. It is clear that p(yij = k) = p(k|f (xi, β), δ) = p(k|xi, Θ),






According to the IAEA manual, the parameters are estimated by maximizing the likelihood
function (2.2), obtaining Θˆ = {βˆ, δˆ}. It is well known that for large data samples, the distribution of
Θ ∈Rp+1 can be approximated by a multivariate Gaussian distribution Np+1(Θˆ , ΣˆΘˆ ), where ΣˆΘˆ is
its estimated variance–covariance matrix, that is, the inverse of the estimated Fisher information
matrix of the model. Note, however, that in the frequentist framework Θˆ ∼ Np+1(Θ , ΣˆΘˆ ). It is
important to remark that the laboratory providing the outputs of the calibration curve, that is Θˆ
and Σˆ
Θˆ
, could be different from the one analysing the patient sample; even though for a consistent
assay, the calibration curve should be constructed with the data provided by the same laboratory
that will analyse the patient data to guarantee that the scoring criteria applied for the construction
of the curve are the same as those applied for patient analysis.
From here, the distribution of the expected count of dicentrics and dispersion index for a given
dose of x, (μ, δ)|x can be approximated by a bivariate normal distribution. This is a straightforward
consequence of the multivariate delta method [19]
(μ, δ)|x∼ N2((f(x, βˆ), δˆ), ∇ · ΣˆΘˆ · ∇t), (2.3)
where ∇ denotes the derivative of (f(x, β), δ) at (βˆ, δˆ), that is,
∇ =
⎛




0 · · · 0 1
⎞
⎠ .
Following these arguments, note that for the Poisson model the distribution of μ|x is
approximated by a univariate normal distribution with expectation f(x, βˆ) and variance equal
to v(x, βˆ) = ∇ · Σˆ
Θˆ
· ∇t, where ∇ is now the gradient of f(x, β) at βˆ. The bivariate normal density
in (2.3) will be denoted as φ(μ, δ|x) and φ(μ|x) will be the normal univariate density used for
the Poisson model. In some situations, the use of a bivariate or univariate normal could be
incompatible with the fact that μ > 0, and in general δ > 1. Then, some approximations have to be
carried restricting the parameters’ domain. For the univariate normal distribution, one solution
is to replace it by a gamma density with the same mean and variance. It is well known that
a larger gamma distribution shape parameter (i.e. the ratio of the square of the mean to the
variance) implies a better normal approximation. As we will see in the next sections, the normal
approximation can be used in a wide range of situations, and it also will be compared with the
gamma approximation. For our purposes μ|x will be called the mean prior distribution, because it
will act as a prior for the inverse regression estimation problem.
Consider the test (patient) data y˜= {y˜1, y˜2, . . . , y˜m}, formed by m count data observations









Note that, because the knowledge of μ implies the knowledge of x, then we can write L(y˜|μ, δ) =
L(y˜|μ, δ, x). Therefore, an application of Bayes’ theorem shows the expression of the posterior
density of the parameters given the test data
f(μ, δ, x|y˜) = L(y˜|μ, δ)p(μ, δ, x)∫
L(y˜|μ, δ)p(μ, δ, x) dμ dδ dx ,
where p(μ, δ, x) is the joint prior density of μ, δ and x. But, p(μ, δ, x) = φ(μ, δ|x)p(x), where p(x)
summarizes the prior information for x. This prior information can come from the characteristics
of the radiation accident, such as the source and the duration of the exposure, etc.
Therefore, marginalizing over μ and δ we obtain the calibrative density of x, that it is the solution
of the inverse regression problem
f(x|y˜) ∝ p(x)
∫
L(y˜|μ, δ)φ(μ, δ|x) dμ dδ. (2.5)
As shown in §3, this calibrative density can be exactly calculated for the Poisson model, solving
completely the problem of the absorbed dose estimation in the most frequent situation.
However, for the two-parameter compound Poisson models the integral in (2.5) does not have
a closed form, thus some approximations are required such as numerical integration or simulation
methods. For this reason, the model will be simplified in §4.
3. The Poisson model







Because the sum of the observations is a sufficient statistic for the parameter of Poisson data,
and the sum of independent Poisson random variables is also Poisson distributed, this likelihood
function is equivalent to the probability function of one Poisson observation evaluated at s, that is,
L(y˜|μ) ∝ p(s|mμ) ∝ e−mμ(mμ)s,
where s=∑mi=1 y˜i. Therefore, the calibrative density (2.5) remains






Note that (3.2) represents the probability function of a mixed Poisson–normal distribution
evaluated at s. Of course, strictly speaking, it is not possible to mix a Poisson with a normal
distribution because the Poisson parameter always has to be positive. However, understanding
this mixture as a purely formal operation, Kemp & Kemp [20] showed that this mixed Poisson
distribution, provided the population mean of the mixing normal is greater than its variance, is





N(a, b2) ∼ Herm
(





This notation means that the μ parameter in the Poisson distribution (left part) is normally




Consequently, (3.2) is the probability that a Hermite random variable takes a value equal to s.
Specifically, it can be directly shown that the probability (3.2) can be obtained from the Hermite
probability recursion described in [21]
(r + 1)qr+1(x) = (mf(x, βˆ) − m2v(x, βˆ))qr(x) + m2v(x, βˆ)qr−1(x),
with q0(x) = exp(−mf(x, βˆ) + m2v(x, βˆ)/2) and defining q−1(x) = 0, provided that f(x, βˆ) −
mv(x, βˆ) ≥ 0. This last inequality is achieved for most of the studied examples, for the range of
interest of the absorbed dose x. In a hypothetical situation where this inequality was not achieved,
that is f(x, βˆ) − mv(x, βˆ) < 0, expression (3.2) mathematically does not make sense (the dispersion
coefficient cannot be greater than 2) and it is therefore better to replace the mean prior normal
density φ(μ|x) by a gamma density Γ (μ|x) with the same mean f(x, βˆ) and variance v(x, βˆ). Then,




p(s|mμ)Γ (μ|x) dμ. (3.3)
Because mixing a Poisson with a gamma produces an NB distribution, it can be shown that qs(x)
in (3.3) is the probability that an NB random variable, with mean mf(x, βˆ) and variance m2v(x, βˆ) +
mf(x, βˆ), takes a value equal to s.
The method presented here for the Poisson model, using the gamma distribution as a mean
prior, is exactly the same as the full Bayesian method of Groer & Pereira [9] for the simple case
where f(x, β) = βx. However for other dose–response curves both methods differ. For this simple
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according to notation in §2, where B(·) denotes Euler’s Beta function. The distribution function of
this calibrative density can be expressed in terms of the hypergeometric function.
The following example illustrates how this methodology is applied to a real dataset.
(a) Example: Cobalt-60 gamma rays irradiation
Here we consider data from an inter-laboratory comparison for the semi-automated dicentric
assay undertaken as part of the Multibiodose project (a large-scale European biodosimetry
project) [22]. This dataset (table 1) is based on blood samples from eight healthy donors
which were irradiated in vitro with cobalt-60 gamma rays at a high-dose rate of 0.27 Gy min−1
simulating acute whole body exposure. The data presented here were collated and analysed
using the Metafer 4 automated analysis system (MetaSystems, Altlussheim, Germany) at a
single participating laboratory, using the ‘BfS’ image analysis classifier (system settings—further
information in Romm et al. [22]).
The u figures shown in table 1 are the values of the u-test statistic of Rao & Chakravarti [23],
which is a normalized sample dispersion index
u= (d − 1)
√
n − 1























Figure 1. Observed means (dots), plus/minus twice their standard errors (error bars), and predicted means (solid line) of the
number of dicentrics for Poisson fitting, based on the data in table 1, omitting the 1.5 Gy test data. (Online version in colour.)
Table 1. Frequency distributions of the number of dicentrics after exposure to six doses of gamma rays, and the samplemeans,
dispersion coefficients and u values for each distribution. Test data in italics.
no. dicentrics
dose (Gy) 0 1 2 3 4 y¯ d u
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
0.25 2185 8 0.004 0.997 −0.113
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
0.75 2550 44 1 0.018 1.026 0.952
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.00 2231 54 2 0.025 1.044 1.503
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.50 1712 96 3 0.056 1.003 0.092
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.50 1196 123 7 1 0.105 1.038 0.985
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.00 1070 320 41 6 1 0.295 1.012 0.334
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
where d= s2y/y¯ is the sample dispersion coefficient, n the sample size (number of cells) and
z= ny¯ the total number of count events (number of dicentrics). When d is close to 1 then the
data follow an equidispersed distribution. If the value of the u statistic is higher (lower) than
(-)2, the distribution can be considered over- (under-) dispersed. The u-test is suggested by the
IAEA [3] and in fact it is equivalent to the classical Fisher dispersion test. According to the u
values shown in table 1, equidispersion of the calibration data can be assumed, thus justifying the
use of a Poisson regression model.
The 1.5 Gy row was removed from the calibration dataset to be used as test data. This means
that the true dose is known and it is possible to compare it with the resulting calibrative density.
Following notation in §3, s= 102 and m= 1811, i.e. 102 scored dicentrics in 1811 blood cells.
In this example, for high-dose rate gamma-radiation exposure, an appropriate dose–response
curve, i.e. the regression model, is a second degree polynomial without intercept [3], f(x, β) =
β2x2 + β1x (figure 1). In biodosimetry, this is called the linear-quadratic dose–response curve. The
intercept has been removed because we assume that for a dose x= 0 the expected number of
dicentrics will be zero (for the 0 Gy sample there was only 1 dicentric in a total of 2592 blood




Table 2. BIC values using a second degree polynomial dose–response curve without constant term for the different models.
model NB Hermite NA Poisson
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
BIC 4088.834 4085.594 4085.524 4079.639
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
mean response is not common, and a log-link mean response is the usual approach. However,
in biodosimetry, the linear-quadratic dose–response curve has a biophysical interpretation [3]
and is one of the most frequently employed in practice. Some problems could occur maximizing
the likelihood function because β1 and β2 have to be necessarily positive. To ensure this, it is
sometimes necessary to use numerical algorithms allowing constrains in the parameter domain.
Table 2 shows the Bayesian information criterion (BIC) values for the four different response
distributions treated in this work from the calibration data. These values support the use of the
Poisson model. So for a Poisson response the maximum-likelihood parameter estimates and their
estimated covariance matrix are the following:
— Fitted coefficients:
βˆ1 = 3.126 × 10−3 and βˆ2 = 2.537 × 10−2.









As has been commented in §2, μ|x will follow a normal or a gamma distribution with mean










and therefore v(x, βˆ) = Σˆ22x4 + 2Σˆ21x3 + Σˆ11x2.
According to (3.2) and (3.3), for a normal or a gamma mean prior, the predictive posterior
distribution q102(x) represents the probability of a Hermite or NB random variable taking a
value of 102 counts, both with same mean 45.939x2 + 5.661x and variance 8.913x4 − 22.553x3 +
69.571x2 + 5.661x.
Despite the real dose being known, firstly, a non-informative prior dose distribution is chosen
in order to not take advantage of this fact, so p(x) ∝ 1. Secondly, for our purposes of comparing
results, we define an informative prior dose distribution assuming we do not know the real dose
of the test data, but we observe a mean of 0.056 dicentrics per cell, then by comparison with
table 1 it can reasonably be estimated that the dose is between 1 and 2.5 Gy. A simple informative
prior could be a gamma whose mean is in the midpoint of this interval, i.e. 1.75, and whose
standard deviation is in the halfway from the mean to cover this interval, i.e. 0.375. For a gamma
distribution with this mean and standard deviation, the 95.67% of the values fall in the region of
1.75 ± 2 × 0.375.
Figure 2 shows the plot of the three densities of the estimated dose for the data test. Note how
these results incorporate the real dose (1.5 Gy) and show the similarities found using both mean
priors. Note that the gamma mean prior is moderately more conservative.
To use the normal mean prior (3.2) for this calibration set, the following condition must be
satisfied: f(x, βˆ) − mv(x, βˆ) ≥ 0. It holds when x≤ 3.337 Gy, and this could also be used as prior
information about the dose, that is, p(x) ∼ U(0, 3.337). For the range of the likely doses studied,
the minimum value of the shape parameter of the mean prior gamma is 328.616, so the gamma or
normal mean priors are practically indistinguishable.














Figure 2. Calibrative densities of the 1.5 Gy test data calculated from a normal (blue/dotted line) and a gamma (red/dashed-
dotted line) mean prior with non-informative prior dose distribution, and for a gammamean prior with informative prior dose
distribution (green/solid line). Red and blue curves are indistinguishable.
Table 3. Statistics summary of the calibrative densities for a normal (a) and a gamma (b) mean prior with non-informative
prior dose distribution, and for a gammamean prior with informative prior dose distribution (c).
model mode expected s.d. 95% CI
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(a) 1.430 1.432 0.081 (1.277, 1.594)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(b) 1.430 1.432 0.081 (1.277, 1.593)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(c) 1.443 1.445 0.078 (1.294, 1.602)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(b) Example: analysis of doses in thyroid cancer patients
This example illustrates how our methodology can be applied having only the fitted parameters
of the dose–response curve, without knowing the calibration points. Serna et al. [24] studied
chromosomal damage in lymphocytes of thyroid cancer patients after radioiodine treatment. The
authors did a micronuclei assay in binucleated cells of blood samples from 25 patients 3 days after
Iodine-131 (3.7 GBq) exposure.
The in vitro calibration curve was fitted by a linear-quadratic model with intercept, f(x, β) =
Gβ2x2 + β1x + β0 according to Poisson’s law, and the estimate of β0 was not taken into account,
because the authors in [24] argued that the intercept could change for each patient. Constant
G is the Lea–Catcheside generalized dose-protraction factor, which modifies the quadratic term
according to the temporal pattern of exposure, being G= 1 for the in vitro assay. The authors
calculated the following parameter estimates (βˆi ± SE(βˆi))
βˆ1 = (13.6 ± 5.5) × 10−3, βˆ2 = (3.7 ± 1.6) × 10−2, ρ = −0.89,
where ρ is the correlation coefficient for βˆ1 and βˆ2. The patients were subjected to ablative
radioiodine treatments for post-surgical thyroid remnants. Consequently, they had a prolonged
exposure lasting several days and which means, the temporal pattern of exposure was different
than that of the in vitro assay. Taking into account the exposure profile of the Iodine-131 treatment,

















Figure 3. Calibrative densities of [24] Patient 1 test data calculated from a gamma mean prior density, with a U (0, 2)
(green/solid line), aU (0, 4.5) (red/dashed-dotted line) prior dose distribution and a improperU (0,+∞) (blue/dotted line)
prior dose distribution.
Then β0, the background for each patient, can be estimated counting the micronuclei of the
patient from a blood sample taken before the treatment, information provided in [24]. This leads to
the fitted regression model f(x, βˆ) =Gβˆ2x2 + βˆ1x + βˆ0 with a covariance matrix that incorporates
the variance of βˆ0 without correlation with βˆ1 and βˆ2.
To illustrate our techniques we are going to estimate the absorbed dose for Patient 1, but the
same can be done for the others. Patient 1 presented 487 normal cells and 13 cells with just one
micronucleus each. Before the treatment five micronuclei where found in 500 blood cells, thus
βˆ0 = (10 ± 4.450) × 10−3. The u-statistic of the test data is −0.395, so this is compatible with the
Poisson model.
Therefore, μ|x will be considered to follow a distribution with mean f(x, βˆ) =Gβˆ2x2 + βˆ1x + βˆ0















The condition f(x, βˆ) − mv(x, βˆ) ≥ 0 is held when x≤ 0.880 Gy. This range of doses is very small
for our purposes and consequently a gamma mean prior is preferred instead of a normal.
According to (3.3), for a gamma mean prior, the predictive posterior distribution q13(x)
represents the probability of an NB random variable taking a value of 13 counts, with mean
0.185x2 + 6.8x + 5 and variance 0.006x4 − 0.399x3 + 7.987x2 + 6.8x + 9.95.
Three calibrative densities have been calculated applying two different proper uniform prior
dose distributions, both using information given in [24]. An administered radioiodine activity
that produces a blood dose less than 2 Gy is considered safe, so we could take a uniform dose
prior distribution from 0 to 2, assuming that doctors use prudent doses. On the other hand,
the calibration curve was calculated up to a dose of 4.5 Gy, so another uniform dose prior
distribution could be from 0 to 4.5. An improper uniform prior dose distribution from 0 to +∞ is
also applied.
Figure 3 shows the plot of the three densities of the estimated dose for the data test. Their
statistics are indicated in table 4. These results agree with those displayed in [24], where the dose





Table 4. Statistics summary of the calibrative densities for two proper and one improper uniform dose priors.
prior dose distribution mode expected s.d. 95% CI
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
U (0, 2) 1.140 1.141 0.481 (0.203, 1.945)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
U (0, 4.5) 1.140 1.561 0.858 (0.203, 3.615)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
U (0,+∞) 1.140 1.593 0.921 (0.253, 3.829)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4. The simplified compound Poisson calibration model
We now consider a dataset that follows a compound Poisson distribution. The likelihood function
of the test data has been previously described in (2.4), and the calculation of the calibrative
density (2.5) requires to use numerical integration or Monte Carlo methods. However, the model
can be simplified by replacing δ in L(y˜|μ, δ) with the MLE δˆ obtained from the calibration data.
The performance of this simplification is analysed and compared in the example §3a. Then
the likelihood function L(y˜|μ, δˆ), which we prefer to denote as L(y˜, δˆ|μ), is equivalent to the
probability function of the sum of the observations, that is the probability function of a compound
Poisson observation,
L(y˜, δˆ|μ) ∝ p(s, δˆ|mμ),




p(s, δˆ|mμ)φ(μ|x) dμ (4.1)




p(s, δˆ|mμ)Γ (μ|x) dμ (4.2)
when the mean prior is gamma distributed. Expressions (4.1) and (4.2) correspond to the
probability function of mixed compound Poisson random variables, where the mixing density
is respectively normal or gamma, evaluated at s. The operations of compounding and mixing are


























δˆ − 1 , 1 +
mv(x, βˆ)
(δˆ − 1)f(x, βˆ)
)∨
Pois(δˆ − 1). (4.3)
This is providing that (4.1) and (4.2) are, respectively, the probability functions of compound









δˆ − 1 , 1 +
mv(x, βˆ)






δˆ − 1 , 1 +
mv(x, βˆ) log(δˆ)







and Hermite : F
(
mf(x, βˆ)
2(δˆ − 1) , 1 +
mv(x, βˆ)
2(δˆ − 1)f(x, βˆ)
)∨




Here F (μF , δF ) indicates a Hermite or an NB distribution, according to (4.1) or (4.2),
parametrized by its population mean and dispersion index. When F is the Hermite distribution,
these representations make sense only when f(x, βˆ)(δˆ − 1) ≥mv(x, βˆ) for the NA, f(x, βˆ)(δˆ − 1) ≥
mv(x, βˆ) log(δˆ) for the NB and 2f(x, βˆ)(δˆ − 1) ≥mv(x, βˆ) for the Hermite.
Compound NB distributions have been studied and applied in several publications.
Properties, characterizations and references can be found in [16]. Compound Hermite
distributions are less common, so far there is one recent publication [25] that studies the
continuous compound Hermite gamma distribution.
When F (μF , δF ) is NB, the probabilities of the associated compound distributions can be
calculated using the Panjer recursion formula [26]. This formula is based on the fact that the
probabilities pn = P(X = n) of a random variable X distributed as a NB(μF , δF ) satisfy a first-
order recurrence relation pn = pn−1(a + b/n), where a= (δF − 1)/δF and b= (μF − δF + 1)/δF .
Then, if the probabilities of the generalizing distribution are denoted as fk, the probabilities qi
of the corresponding NB compound distribution satisfy the recursion [26]








fjqi−j, i≥ 1. (4.5)
Expression (4.5) can be efficiently used to calculate (4.2). The values of a and b will be taken
according to the chosen distribution of the observations, using the corresponding expression
of μF and δF of the NB (F ) indicated in (4.4). In the next section we will give an example
of application.
WhenF is Hermite, the probabilities of a Hermite compound distribution cannot be calculated
using the Panjer recursion formula because the probabilities of the Hermite do not follow a
linear recursion. To calculate the probabilities in this case we state and prove (in appendix A)
the following proposition:
Proposition 4.1. Let qn, n= 0, 1, 2 . . . be the probabilities of a compound Hermite distribution of the
form Herm(μh, δh)
∨P , where P is a count distribution with probabilities fk, k= 0, 1, 2 . . .. We define
rj =
∑j












and q0 = exp(μh((2 − δh)(f0 − 1) + (δh − 1)(f 20 − 1)/2)).
It is important to remark that, to calculate qs(x) in (4.1) and (4.2), a computationally intensive
direct numerical integration can be done instead to use the Panjer recursion or proposition 4.1.
To this end, it would be enough to obtain numerically the probabilities which are available for a
more wide range of models than those studied in this paper.





Table 5. Frequency distributions of the number ofmicronuclei after exposure to 11 doses of gamma rays, and the samplemeans,
dispersion coefficients and u values for each distribution. Test data in italics.
no. micronuclei
dose (Gy) 0 1 2 3 4 5 6 7 y¯ d u
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
0.00 4887 106 5 2 0.024 1.156 7.839
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
0.10 4773 206 19 2 0.050 1.150 7.526
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
0.25 4261 324 41 12 2 0.090 1.306 15.306
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
0.50 4536 364 76 17 7 0.119 1.449 22.484
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
0.75 4383 512 85 18 2 0.149 1.257 12.876
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.00 4225 636 115 19 5 0.189 1.240 12.009
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1.50 4018 805 139 26 9 1 2 0.243 1.270 13.495
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.00 3499 1194 238 45 13 10 1 0.383 1.209 10.471
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.50 3171 1313 393 94 24 3 2 0.501 1.201 10.077
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3.00 2582 1575 598 190 44 9 2 6 0.722 1.206 10.307
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.00 1974 1674 869 342 102 26 13 2 1.013 1.172 8.628
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(a) Example: high linear energy transfer exposure
Puig & Valero [18] studied the fitting of an experiment of 11 samples of peripheral blood
exposed to different doses of γ -rays (table 5), where the dose rate was 0.93 cGy min−1. For each
sample, approximately 5000 binucleated cells were inspected, and the numbers of micronuclei
were counted.
The u values shown in table 5 confirm the overdispersion, thus Poisson regression is not
adequate.
Similar to the example analysed in §3a the 0.1 Gy data will be removed to be used as test data.
This distribution has a total of 250 micronuclei in a total of 5000 cells so s= 250 and m= 5000.
The appropriate dose–response curve, i.e. the regression model, is again a linear-quadratic
model with intercept, f(x, β) = β2x2 + β1x + β0 (figure 4). Table 6 shows the BIC values for the
four different models studied in this work. Note how these values support the use of the
NB model.
Using the NB model, the maximum-likelihood estimation provides the following results:
— Fitted coefficients:
βˆ0 = 3.639 × 10−2, βˆ1 = 1.156 × 10−1, βˆ2 = 3.241 × 10−2, δˆ = 1.231.
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Figure 4. Observed means (dots), plus/minus twice their standard errors (error bars), and predicted means (solid line) of the
number of micronuclei for NB fitting, based on the data in table 5, omitting the 0.1 Gy test data. (Online version in colour.)
Table 6. BIC values using a second degree polynomial dose–response curve for the different models.
model Poisson Hermite NA NB
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
BIC 67360.01 66537.46 66467.85 66437.93
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Then, the prior densities are:
— Complete Model: According to (2.3), (μ, δ)|x follows a bivariate normal distribution with













1 x x2 0
0 0 0 1
)
,
so the variance-covariance is(
Σˆ33x4 + 2Σˆ32x3 + 2Σˆ31x2 + Σˆ22x2 + 2Σˆ21x + Σˆ11 Σˆ43x2 + Σˆ42x + Σˆ41
Σˆ43x2 + Σˆ42x + Σˆ41 Σˆ44
)
.
For this example, the calibrative density (2.5) is calculated via numerical integration in
order to be compared with those calculated using the simplified models.
— Simplified Models: According to the arguments given in §4, μ|x follows a gamma
or a normal distribution with mean f(x, βˆ) = βˆ2x2 + βˆ1x + βˆ0 and variance v(x, βˆ) =












= (1, x, x2),
so the variance is Σˆ33x4 + 2Σˆ32x3 + 2Σˆ31x2 + Σˆ22x2 + 2Σˆ21x + Σˆ11. According to (4.4),
for a normal or a gamma mean prior, the predictive posterior distribution q250(x)
represents respectively the probability of a compound Hermite- or compound
NB-Logarithmic random variable taking a value of 250 counts, both with same
f(x, βˆ) = 0.032x2 + 0.116x + 0.036, v(x, βˆ) = 3.81 × 10−6x4 + 1.525 × 10−5x3 + 5.842 ×
















Figure 5. Calibrative densities of the 0.1 Gy test data using the complete model (2.5) (green/solid line), and the simplified
ones with a normal (blue/dotted line) and a gamma (red/dashed-dotted line) mean prior density; all with a uniform prior dose
distribution. Blue and red curves are indistinguishable.
Table 7. Statistics summary of the calibrative densities for the complete model, and the simplifiedmodels using a gamma and
a normal mean prior with a uniform prior dose distribution.
model complete S. Norm. p. S. Gam. p.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
mode 0.125 0.115 0.115
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
expected 0.124 0.114 0.114
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
s.d. 0.033 0.034 0.034
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
95% CILB 0.059 0.047 0.047
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
95% CIUB 0.190 0.182 0.181
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
To use the normal mean prior (4.1) in this calibration set for NB responses, there is a condition
to be satisfied: f(x, βˆ)(δˆ − 1) − mv(x, βˆ) log(δˆ) ≥ 0. It is satisfied when x≤ 4.294 Gy. In this example,
this is not a problem and it could be used as prior information about the dose, that is p(x) ∼
U(0, 4.294). For the range of the likely doses studied, the minimum value of the shape parameter
of the mean prior gamma is 179.605, and consequently both gamma and normal mean priors are
almost indistinguishable (red and blue curves in figure 5).
Figure 5 shows the plot of the three densities (one from the complete model and two from
the simplified ones) of the estimated dose for the data test. Note that both calibrative densities
from the simplified models are practically the same. The statistics of these densities are shown
in table 7. These results incorporate the real dose (0.1 Gy) and also show their similarities, chiefly
between the simplified models.
5. Conclusion
In this paper, we have presented several Bayesian-type methods for count data inverse regression,
showing its application in the field of cytogenetic dosimetry. First, in §2 we defined our
methodology for inverse regression, where responses are either Poisson or two-parameter





doses. This methodology leads to a bivariate normal prior density when the responses follow
a two-parameter compound Poisson distribution, and an univariate normal or gamma mean
prior density when the responses follow a Poisson distribution. To use our methodology, only the
estimates of the parameters and covariance matrix of the dose–response curve are required. This
information is available from the standard frequentist analysis suggested by the IAEA manual,
with many examples published by other researchers or laboratories. Therefore, our method is not
a full Bayesian approach because the dose–response curve is estimated using frequentist analysis.
MCMC methods could be used if the models were more complex or the prior densities more
complicated. They might also be used for model averaging, since one might aim to avoid choosing
one of the presented four models, preferring to use a weighted amalgam of them.
The Poisson model is developed in §3, leading to a closed form of the calibrative density. Two
examples of dose estimation based on the dicentric assay are reported.
In §4, we treated two-parameter compound Poisson models, simplifying them to get the
calibrative densities into a closed form. For this purpose, we have presented a method
which involves calculating the probabilities of compound NB distributions, using Panjer’s
recursion [26], and compound Hermite distributions, using a recursion relation described in
proposition 4.1. Another example of dose estimation is shown, based on data obtained with the
micronucleus assay. We have assumed a constant dispersion coefficient, but our methods could
be also extended to dose-dependent dispersion models of the form δij = g(xi, γ ), γ ∈Rq.
The illustrative examples show applications using the most frequent calibrative curves, that
are second-order polynomials (the linear-quadratic model). However, other response functions
can be directly analysed using the same methodology. It should be noted that the approaches
presented here may also prove useful in areas other than biological dosimetry.
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Appendix A. Proof of proposition 4.1
First of all, let us recall some topics related to the probability-generating function (pgf). Given a






where the coefficients of this power series are the probabilities pk = P(X = k) and consequently
the derivatives at s= 0 divided by k! provide the probability mass function of X. The pgf of a
compound probability distribution described in (2.1) is
ΦX(s) = ΦN(Φξ (s)), (A 1)
where ΦN(s) is the pgf of N and Φξ (s) is the common pgf of the ξi [16].
One property of pgf’s is that the sum of independent random variables is a random variable
whose pgf is the product of the pgf’s of the summed variables; e.g. given X and Y independent
random variables with pgf’s ΦX(s) and ΦY(s) respectively, the pgf of X + Y results
ΦX+Y(s) = ΦX(s)ΦY(s). (A 2)
According to Kemp & Kemp [20] the pgf of a random variable X Hermite distributed with
mean μh and dispersion coefficient δh is





therefore, according to (A 1), the pgf of a Herm(μh, δh)
∨P distribution, being ψ(s) the pgf of P , is
φ(s) = eμh{(2−δh)(ψ(s)−1)+(δh−1)(ψ2(s)−1)/2}, (A 4)
thus the probability in 0 is
q0 = φ(0) = eμh{(2−δh)(f0−1)+(δh−1)(f 20 −1)/2}.
Note that ψ2(s) is the pgf of a sum of two independent identically distributed random variables
having both a pgf equal to ψ , so












(2 − δh)(ψ ′(s) − 1) +













































and this finishes the proof.
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